查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
mRNA 疫苗市场 - 2018-2028 年全球行业规模、份额、趋势、机会和预测，按 mRNA 类型、应用、地区和竞争细分
市场调查报告书
商品编码
1321045

mRNA 疫苗市场 - 2018-2028 年全球行业规模、份额、趋势、机会和预测，按 mRNA 类型、应用、地区和竞争细分

mRNA Vaccine Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By mRNA Type, By Application, Region and Competition
出版日期: | 出版商: TechSci Research | 英文 112 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

由于 mRNA 疫苗在生产、安全性、有效性和分销等方面相对于 DNA 疫苗具有多种优势，全球 mRNA 疫苗市场将在预测期内以惊人的速度增长。全球 mRNA 疫苗市场受到癌症、遗传异常和病毒感染髮病率上升的推动。 2020 年，癌症导致约 1000 万人死亡，即近六分之一的死亡，使其成为全球最主要的死因之一。 TAA（肿瘤相关抗原）、TSA（肿瘤特异性抗原）及其相关细胞因子都可以由mRNA疫苗编码和表达，构成了一类重要的癌症疫苗。这些疫苗更适合各种疾病和患者，因为 mRNA 癌症疫苗可以增强体液和细胞免疫。此外，COVID-19大流行的突然爆发和蔓延以及Moderna和辉瑞-BioNTech针对COVID-19疫苗的成功预计将为未来几年mRNA疫苗市场的增长创造新的前景。这反过来又促使许多生物技术和製药公司以及学术研究机构挺身而出，开始研发和开展不同类型mRNA疫苗的临床试验，从而为全球mRNA疫苗的增长创造了丰厚的机会。预测期内的市场。根据 ClinicalTrials.gov 的数据，大约 444 项与 mRNA 疫苗相关的临床研究正处于不同的开发阶段，正在全球不同地区进行。

mRNA疫苗的优点

与大多数疫苗的生产相比，mRNA 疫苗的生产比其他同类疫苗具有优势，因为它不需要使用细胞培养物。由于反应时间快，污染的风险比其他復杂的疫苗生产技术要小。此外，mRNA 疫苗由于其非整合性和细胞内短暂表达而更安全。 mRNA 疫苗利用脂质封装或裸露形式的序列优化 mRNA，在流感病毒、寨卡病毒、狂犬病病毒等动物模型中产生了针对传染病靶标的有效免疫力，特别是近年来。

增加生产 mRNA 疫苗的研究活动

与其他治疗方式相比，mRNA 具有众多优势，例如更高的生物功效、更强的免疫原性以及低毒性水平的多功能递送平台，是该领域正在进行的研究和开发工作的主要驱动力。开发基于 mRNA 的疫苗来预防糖尿病、艾滋病毒、癌症和心血管疾病等传染病或慢性疾病是广泛研究的主题。目前有 430 项临床试验使用 mRNA 疫苗来预防除 COVID-19 以外的疾病。根据 ClinicalTrials.gov 的分析，大多数临床试验是在美国进行的。

宾夕法尼亚大学佩雷​​尔曼医学院的研究人员研製出了一种基于 mRNA 的多价疫苗，可以预防所有 20 种已知的流感病毒亚型。他们采用了与早期尝试创建通用流感疫苗不同的方法，即包含每种亚型特有的抗原，而不仅仅是亚型共享的较小的一组抗原。辉瑞和 Moderna 生产的 SARS-CoV-2 疫苗使用了与该策略相同的 mRNA 技术。 Penn 是开髮用于 COVID-19 疫苗的 mRNA 技术的领导者。

市场细分

全球 mRNA 疫苗市场可以按 mRNA 类型、应用和地区进行细分。根据mRNA类型，市场可分为核苷修饰mRNA、未修饰mRNA和自扩增mRNA。根据应用，市场分为 COVID-19 mRNA 疫苗、非 COVID-19 mRNA 疫苗等。从地区来看，mRNA疫苗可分为北美、欧洲、亚太地区、南美、中东和非洲。

市场参与者

Arcturus Therapeutics Holdings Inc.、BioNTech SE、CureVac NV、Daiichi Sankyo Company Limited.、Ethris GmbH、葛兰素史克plc、Gennova Biopharmaceuticals Ltd、Moderna, Inc.、Pantherna Therapeutics GmbH、Providence Therapeutics、Silence Therapeutics、Translate Bio、VERSAMEB AG、Verve Therapeutics Inc. 是全球 mRNA 疫苗市场的一些领先参与者。

可用的定制

根据给定的市场数据，TechSci Research 可根据公司的具体需求提供定制服务。该报告可以使用以下自定义选项：

公司信息

  • 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场细分

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要行业合作伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量和验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：临床试验分析

  • 正在进行的临床试验
  • 已完成的临床试验
  • 终止的临床试验
  • 按开发阶段分類的管道细目
  • 管道细分（按状态）
  • 按研究类型分類的管道细目
  • 按地区分類的管道明细
  • 临床试验热图

第 5 章：客户之声

第 6 章：全球 mRNA 疫苗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按 mRNA 类型（核苷修饰 mRNA、未修饰 mRNA、自扩增 mRNA）
    • 按应用（COVID-19 mRNA 疫苗、非 COVID-19 mRNA 疫苗、其他）
    • 按地区（北美、欧洲、亚太地区、南美、中东和非洲）
    • 按公司划分 (2022)
  • 产品图
    • 按 mRNA 类型
    • 按申请
    • 按地区

第 7 章：北美 mRNA 疫苗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按 mRNA 类型（核苷修饰 mRNA、未修饰 mRNA、自扩增 mRNA）
    • 按应用（COVID-19、非 COVID-19、其他）
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 8 章：欧洲 mRNA 疫苗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按 mRNA 类型（核苷修饰 mRNA、未修饰 mRNA、自扩增 mRNA）
    • 按应用（COVID-19、非 COVID-19、其他）
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙

第 9 章：亚太地区 mRNA 疫苗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按 mRNA 类型（核苷修饰 mRNA、未修饰 mRNA、自扩增 mRNA）
    • 按应用（COVID-19、非 COVID-19、其他）
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚

第 10 章：南美 mRNA 疫苗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按 mRNA 类型（核苷修饰 mRNA、未修饰 mRNA、自扩增 mRNA）
    • 按应用（COVID-19、非 COVID-19、其他）
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第11章：中东和非洲mRNA疫苗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按 mRNA 类型（核苷修饰 mRNA、未修饰 mRNA、自扩增 mRNA）
    • 按应用（COVID-19 mRNA 疫苗、非 COVID-19 mRNA 疫苗、其他）
    • 按国家/地区
  • MEA：国家分析
    • 南非 mRNA 疫苗
    • 沙特阿拉伯 mRNA 疫苗
    • 阿联酋 mRNA 疫苗

第 12 章：市场动态

  • 司机
  • 挑战

第 13 章：市场趋势与发展

  • 最近的发展
  • 併购
  • 产品发布

第 14 章：全球 mRNA 疫苗市场：SWOT 分析

第 15 章：波特的五力分析

  • 行业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第16章：竞争格局

  • 商业概览
  • 产品供应
  • 最近的发展
  • 财务（据报导）
  • 主要人员
  • SWOT分析
    • Arcturus Therapeutics Holdings Inc.
    • BioNTech SE
    • CureVac NV
    • Daiichi Sankyo Company Limited.
    • Ethris GmbH
    • GlaxoSmithKline plc
    • Gennova Biopharmaceuticals Ltd
    • Moderna, Inc.
    • Pantherna Therapeutics GmbH
    • Providence Therapeutics
    • Silence Therapeutics
    • Translate Bio
    • VERSAMEB AG
    • Verve Therapeutics Inc.

第 17 章：战略建议

简介目录
Product Code: 14521

Global mRNA vaccine market is poised to grow at an impressive rate during the forecast period on account of the various benefits of mRNA vaccine over DNA vaccine in terms of production, safety, efficacy, and distribution, among others. Global mRNA Vaccine Market is driven by the rising incidence of cancer, genetic abnormalities, and viral infections. Approximately 10 million deaths, or nearly one in six deaths, happened due to cancer in 2020, making it one of the top causes of death globally. TAA (tumor-associated antigens), TSA (tumor-specific antigens), and their related cytokines can all be encoded and expressed by mRNA vaccines, which constitute a significant class of cancer vaccines. These vaccines are more adaptable to various diseases and patients because mRNA cancer vaccines can boost both humoral and cellular immunity. Besides, the sudden outbreak and spread of the COVID-19 pandemic and the success of Moderna's and Pfizer- BioNTech's vaccines against COVID-19 are expected to create new prospects for growth of the mRNA vaccine market in the coming years. This has, in turn, resulted in many biotechnology & pharmaceutical companies and academic & research institutions coming forward and starting research and development and launching clinical trials for the development of different types of mRNA vaccines, thereby creating lucrative opportunities for the growth of global mRNA vaccine market during the forecast period. According to clinicaltrials.gov, around 444 clinical studies related to mRNA Vaccines are in different phases of development being conducted across different parts of the globe.

The important reason for encouraging extensive study and deployment of mRNA vaccines is their numerous distinctive benefits. One of the main causes for the development of mRNA vaccines is their convenience of production. Simple in form, its active component, RNA, is often produced in vitro utilizing linear DNA as a template. Through codon optimization, nucleoside modification, and an additional delivery method, the stability and translation efficiency of mRNA can be enhanced during this process to create a nucleic acid vaccine with high specificity and resilient stability. The vaccine's safety is another important aspect that encourages widespread use. There is no potential risk of infection or genetic damage because the mRNA does not integrate into the host genome.

mRNA vaccines create proteins that cause human bodies to generate an immune response. Since these vaccines don't involve live viruses, there is absolutely no risk of getting sick after receiving them. The body quickly breaks down mRNA, and cells don't readily take up foreign mRNA. Recent technological advancements have improved the stability of the mRNA molecule and wrapped the molecules in lipids to improve cell delivery effectiveness. These developments boost the production of spike protein in your cells, triggering a stronger immunological response.

Furthermore, owing to recent technological developments in enhanced translation, stability, and delivery methods, messenger RNAs have emerged as a promising therapeutic tool. In fact, mRNA vaccines have opened the door to new pharmacological fields and have become a significant therapeutic class. The development of vaccines is entering a new age because of these mRNA vaccines, which support next-generation vaccinations.

Industry expansion is anticipated to be supported during the projected time by increased investments in the development of cutting-edge and efficient mRNA vaccines. For instance, American mRNA therapeutic developer Arcturus Therapeutics established a Japanese company in Chiba Prefecture in April 2021 as part of a joint venture with Axcelead, Inc., and is currently building a production plant in Minamisoma City, Fukushima Prefecture. In the upcoming years, such investments are probably going to supplement market expansion.

Advantages of mRNA Vaccines

mRNA vaccine production has advantages over the other counterparts, when compared to the production of most vaccines, since it does not require the use of cell cultures. The risk of contamination is smaller than what is seen with other sophisticated vaccine manufacturing techniques because of its quick reaction time. Additionally, mRNA vaccines are safer due to their non-integrative nature and transitory expression within cells. Using lipid-encapsulated or naked forms of sequence-optimized mRNA, mRNA vaccines have produced potent immunity against infectious disease targets in animal models of influenza virus, Zika virus, rabies virus, and others, particularly in recent years.

Increasing Research Activities to produce mRNA-based Vaccines

The numerous benefits mRNA offers over other therapeutic modalities, such as higher biological efficacy, enhanced potent immunogenicity, and versatile delivery platforms at low toxicity levels, are the main drivers of the ongoing research and development efforts being made in this field. The development of mRNA-based vaccines to prevent infectious or chronic diseases like diabetes, HIV, cancer, and cardiovascular diseases is the subject of extensive research. There are currently 430 clinical trials using mRNA vaccines to prevent diseases other than COVID-19. The majority of these clinical trials, according to an analysis by Clinicaltrials.gov, are conducted in the United States.

A multivalent, mRNA-based vaccine that protects against all 20 known influenza virus subtypes has been created by researchers at the Perelman School of Medicine at the University of Pennsylvania. They take a different approach from earlier attempts to create a universal flu vaccine by including antigens unique to each subtype rather than just a smaller set of antigens shared by subtypes. The SARS-CoV-2 vaccines made by Pfizer and Moderna used the same mRNA technology as this strategy. Penn was a leader in the development of the mRNA technology used in those COVID-19 vaccines.

Market Segmentation

Global mRNA Vaccine Market can be segmented by mRNA type, by application, and by region. Based on mRNA type, the market can be divided into nucleoside-modified mRNA, unmodified mRNA, and self-amplifying mRNA. Based on application the market is divided into COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, and others. Regionally, the mRNA Vaccine can be categorized into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

Arcturus Therapeutics Holdings Inc., BioNTech SE, CureVac N.V., Daiichi Sankyo Company Limited., Ethris GmbH, GlaxoSmithKline plc, Gennova Biopharmaceuticals Ltd, Moderna, Inc., Pantherna Therapeutics GmbH, Providence Therapeutics, Silence Therapeutics, Translate Bio, VERSAMEB AG, Verve Therapeutics Inc., are some of the leading players operating in the Global mRNA Vaccine Market.

Report Scope

In this report, Global mRNA Vaccine Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Global mRNA Vaccine Market, By mRNA Type:

  • Nucleoside-modified mRNA
  • Unmodified mRNA
  • Self-Amplifying mRNA

Global mRNA Vaccine Market, By Application:

  • COVID-19 mRNA Vaccines
  • Non COVID-19 mRNA Vaccines
  • Others

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global mRNA Vaccine Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Clinical Trial Analysis

  • 4.1. Ongoing Clinical Trials
  • 4.2. Completed Clinical Trials
  • 4.3. Terminated Clinical Trials
  • 4.4. Breakdown of Pipeline, By Development Phase
  • 4.5. Breakdown of Pipeline, By Status
  • 4.6. Breakdown of Pipeline, By Study Type
  • 4.7. Breakdown of Pipeline, By Region
  • 4.8. Clinical Trials Heat Map

5. Voice of Customer

6. Global mRNA Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 6.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 6.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 6.2.4. By Company (2022)
  • 6.3. Product Map
    • 6.3.1. By mRNA Type
    • 6.3.2. By Application
    • 6.3.3. By Region

7. North America mRNA Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 7.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States mRNA Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By mRNA Type
        • 7.3.1.2.2. By Application
    • 7.3.2. Canada mRNA Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By mRNA Type
        • 7.3.2.2.2. By Application
    • 7.3.3. Mexico mRNA Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By mRNA Type
        • 7.3.3.2.2. By Application

8. Europe mRNA Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 8.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 8.2.3. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France mRNA Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By mRNA Type
        • 8.3.1.2.2. By Application
    • 8.3.2. Germany mRNA Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By mRNA Type
        • 8.3.2.2.2. By Application
    • 8.3.3. United Kingdom mRNA Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By mRNA Type
        • 8.3.3.2.2. By Application
    • 8.3.4. Italy mRNA Vaccine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By mRNA Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Spain mRNA Vaccine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By mRNA Type
        • 8.3.5.2.2. By Application

9. Asia-Pacific mRNA Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 9.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 9.2.3. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China mRNA Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By mRNA Type
        • 9.3.1.2.2. By Application
    • 9.3.2. India mRNA Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By mRNA Type
        • 9.3.2.2.2. By Application
    • 9.3.3. Japan mRNA Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By mRNA Type
        • 9.3.3.2.2. By Application
    • 9.3.4. South Korea mRNA Vaccine Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By mRNA Type
        • 9.3.4.2.2. By Application
    • 9.3.5. Australia mRNA Vaccine Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By mRNA Type
        • 9.3.5.2.2. By Application

10. South America mRNA Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 10.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil mRNA Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By mRNA Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Argentina mRNA Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By mRNA Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Colombia mRNA Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By mRNA Type
        • 10.3.3.2.2. By Application

11. Middle East and Africa mRNA Vaccine Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 11.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 11.2.3. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa mRNA Vaccine Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By mRNA Type
        • 11.3.1.2.2. By Application
    • 11.3.2. Saudi Arabia mRNA Vaccine Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By mRNA Type
        • 11.3.2.2.2. By Application
    • 11.3.3. UAE mRNA Vaccine Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By mRNA Type
        • 11.3.3.2.2. By Application

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Merger Acquisition
  • 13.3. Product launches

14. Global mRNA Vaccine Market: SWOT Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. Business Overview
  • 16.2. Product Offerings
  • 16.3. Recent Developments
  • 16.4. Financials (As Reported)
  • 16.5. Key Personnel
  • 16.6. SWOT Analysis
    • 16.6.1. Arcturus Therapeutics Holdings Inc.
    • 16.6.2. BioNTech SE
    • 16.6.3. CureVac N.V.
    • 16.6.4. Daiichi Sankyo Company Limited.
    • 16.6.5. Ethris GmbH
    • 16.6.6. GlaxoSmithKline plc
    • 16.6.7. Gennova Biopharmaceuticals Ltd
    • 16.6.8. Moderna, Inc.
    • 16.6.9. Pantherna Therapeutics GmbH
    • 16.6.10. Providence Therapeutics
    • 16.6.11. Silence Therapeutics
    • 16.6.12. Translate Bio
    • 16.6.13. VERSAMEB AG
    • 16.6.14. Verve Therapeutics Inc.

17. Strategic Recommendations